Randomized Phase II Study Comparing Cabozantinib (NSC 761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

Randomized Phase II Study Comparing Cabozantinib (NSC 761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CABOSUN
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2018 According to an Ipsen media release, data from this trial will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) (2018).
    • 17 May 2018 According to the Ipsen media release, European Commission (EC) has approved Cabometyx (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate or poor-risk advanced renal cell carcinoma carcinomain the European Union, Norway and Iceland, based on the data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top